Published in Rev Pneumol Clin on January 01, 2007
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol (2011) 1.92
Hemophilia A induced by ipilimumab. N Engl J Med (2011) 1.55
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
[Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma]. Med Sci (Paris) (2011) 1.38
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res (2008) 1.21
Rituximab therapy for HIV-associated Castleman disease. Blood (2003) 1.16
Kidney injuries related to ipilimumab. Invest New Drugs (2014) 1.03
Vemurafenib and radiosensitization. JAMA Dermatol (2013) 0.95
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol (2012) 0.94
Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp. Am J Surg Pathol (2016) 0.86
Mycosis fungoides-type cutaneous T-cell lymphoma and neutrophilic dermatosis. Arch Dermatol (2005) 0.86
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. Cancer Res (2013) 0.84
Severe meningo-radiculo-neuritis associated with ipilimumab. Invest New Drugs (2012) 0.82
The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma. Br J Cancer (2008) 0.81
Defining the clinical condition of cancer patients: it is time to switch from performance status to nutritional status. Support Care Cancer (2011) 0.79
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]. Rev Prat (2010) 0.78
Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol (2012) 0.78
Correlation of phenotype/genotype in a cohort of 23 xeroderma pigmentosum-variant patients reveals 12 new disease-causing POLH mutations. Hum Mutat (2014) 0.78
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res (2015) 0.77
Scurvy in liver transplant patients. J Am Acad Dermatol (2006) 0.75
Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma. Acta Derm Venereol (2017) 0.75
Melanoma arising from a long-standing pigmented trichoblastoma: clinicopathologic study with complementary aCGH/mutational analysis. Am J Dermatopathol (2014) 0.75